Night of the Living Drug: The Mortuary of Molecules Has Come Alive!

Drug repurposing is giving pharmaceutical companies a way to revisit compounds that once appeared to have reached the end of their life.

Image

How Abandoned Molecules Find a Second Life in Drug Discovery

A failed trial, a discontinued programme, or an abandoned commercial strategy does not always mean a molecule has nothing left to offer.

New biological insights, improved delivery systems, and better patient selection can change a molecule’s prospects.

For drug discovery teams, the challenge is knowing which compounds deserve another chance, and which should remain in the past.

Drug development rarely follows a straight line. A compound may show biological activity but fail to produce meaningful benefits in a clinical trial. Another may work in a narrow patient group that the original study did not identify.

An even third may be discontinued because a company changes its portfolio priorities, merges with another business, or decides that the expected commercial return does not justify further investment.

These outcomes are not interchangeable. A molecule can fail as a product without its underlying biology being disproven. Equally, a commercially abandoned drug is not necessarily a scientifically promising one.

Of the reasons why pharmaceutical companies discontinue promising candidates, insufficient efficacy, competition from better treatments, commercial decisions, safety concerns, and research-design problems are all included.

Limited access to historical trial data, funding gaps, and intellectual property barriers are all obstacles to restarting development.

Drug discovery teams need to understand why a programme stopped before deciding whether to reopen it. A failed endpoint might justify a new look at patient selection or an event of serious toxicity may demand a much higher threshold of evidence.

A portfolio decision could leave a genuine opportunity for another developer, provided the relevant data and rights remain accessible.

The opportunity is therefore not to resurrect every discontinued candidate but to separate scientific failure, development failure, and commercial failure before committing resources.

View interview How Should Pharma Companies Audit AI Vendors?

How Should Pharma Companies Audit AI Vendors?

“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."

Image

From Dusty Skeletons to Reanimated Candidates

Drug repurposing usually means investigating an existing medicine for a different indication or patient population.

Drug repositioning is also used to describe efforts to advance previously studied, unapproved compounds into new therapeutic roles. In practice, the terminology often overlaps.

The strategy can reduce some uncertainties because researchers may already understand a compound’s pharmacology, formulation, manufacturing requirements, and safety profile.

But those advantages depend on what has actually been established. Experience in one disease does not prove efficacy in another, and a known safety profile does not automatically apply to a different dose, treatment duration, or patient population.

Several routes can bring a molecule back into the world of the living!

New biology changes the picture

Research may reveal that a drug affects a pathway involved in a different disease.

Improved understanding of disease mechanisms can turn an earlier observation into a testable hypothesis. Modern genetic data, molecular profiling, and better disease models can help researchers identify where that hypothesis is most credible.

The critical step is to establish a plausible link between the drug's mechanism and the new indication. A database association or computational prediction can nominate a candidate, but experimental work must determine whether the effect is real and relevant.

Better patient selection reveals narrow lanes of opportunity

A treatment may produce a weak result across a broad population while offering a stronger rationale in a biologically defined subgroup. Biomarkers and improved patient stratification can help researchers test this possibility.

However, a subgroup discovered after a trial fails should not automatically be treated as proof of efficacy. Researchers need to assess whether the signal is statistically credible, biologically coherent, and reproducible. A prospective study may be necessary to establish whether the apparent benefit translates into clinical value.

A different formulation or combination changes the proposition

Drug delivery can affect where a compound travels, how long it remains active, and whether patients can tolerate the required exposure.

A new formulation may address a genuine limitation, although it cannot erase an intrinsic safety problem.

Combination therapy can be another problem. An existing drug may have limited activity alone but contribute to a useful effect alongside another treatment. That needs evidence of complementary mechanisms, manageable interactions, and a benefit that justifies the added complexity.

For R&D teams, these routes represent different investment cases. Each requires its own evidence plan, development costs, and definition of success.

Image

What Does Successful Drug Resurrection Look Like?

Thalidomide illustrates how a drug’s therapeutic role can change dramatically over time, although its history also demonstrates the consequences of inadequate safety protection.

The medicine became infamous for severe birth defects following its use during pregnancy decades ago. Researchers subsequently established therapeutic uses in specific conditions. In the U.S., the National Cancer Institute lists thalidomide with dexamethasone as an approved treatment option for certain patients with newly diagnosed multiple myeloma. Its use is subject to a dedicated risk-management programme.

This is not a simple story of a failed drug returning unchanged. It shows that therapeutic value depends on the indication, patient population, evidence, and safeguards surrounding use. The medicine’s history cannot be separated from its risks, and its later applications do not make those risks disappear.

The wider lesson is that a new indication must be evaluated on its own merits. A compound’s established activity can justify further investigation, but it cannot substitute for evidence of safety and effectiveness in the proposed use.

The evidence required for a second life

A credible resurrection programme needs more than an intriguing mechanism or a retrospective signal. It requires a structured assessment of:

• Biological rationale: Does the drug act on a mechanism that matters to the proposed disease?
• Evidence quality: Are the original studies, negative findings, safety data, and trial results available for independent review?
• Clinical relevance: Is there a plausible route to meaningful patient benefit, rather than only a laboratory effect?
• Safety and dosing: Can researchers define an appropriate exposure and assess the risks in the new population?
• Development feasibility: Can the team secure the necessary rights, funding, manufacturing capacity, and regulatory pathway?

The U.S. Food and Drug Administration (FDA) has renewed its focus on drug repurposing for unmet medical needs. Its initiative considers potential new uses for approved medicines where safety and effectiveness data could support an updated indication or use in a different population.

The agency has also highlighted the difficulty of generating evidence for older medicines when commercial incentives are weak. This does not lower the evidence threshold. The question remains whether the available data, together with any new studies, support the proposed use.

View interview AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech

Kate O’Reilly, President & Chair of the Healthcare Businesswomen’s Association (HBA) Dublin-Ireland Chapter & Healthcare Transformation Partner at Roche, discusses AI in pharma, patient engagement, and the future of healthcare innovation.

Image

Why Do Promising Compounds Remain Buried?

Scientific merit alone does not bring a drug back into development. The economics can be difficult, particularly when the compound is generic or its original patents have expired.

A company that funds new trials may struggle to recover its investment if competitors can sell the same active ingredient without bearing those development costs.

Ownership can also be fragmented across sponsors, research institutions, datasets, and intellectual property agreements.

Even when a candidate looks scientifically attractive, the team may lack the resources to generate the evidence needed for regulatory approval.

The National Institutes of Health (NIH) has highlighted this problem through its Repurposing Generic Drugs Evidence Package Challenge.

The NIH initiative seeks evidence-based opportunities to investigate existing generic medicines for conditions where further treatment options are needed. It recognises a central tension that an inexpensive medicine can offer substantial patient value, yet limited commercial incentives can leave important research unfunded.

For R&D teams, this creates several strategic questions. Who will finance the next study? Who controls the compound and its historical data? Can a developer establish sufficient intellectual property or another defensible commercial position? Will health systems adopt the medicine if it succeeds?

These help determine whether a promising hypothesis can become a viable drug development programme.

A Smarter Framework for Bringing Drugs Back

Pharmaceutical companies can improve their approach by treating discontinued compounds as a portfolio of evidence-led opportunities, rather than as a collection of forgotten assets.

A practical screening process should begin with the original reason for discontinuation. Teams should then reassess the scientific hypothesis against current knowledge, review the complete safety and efficacy record, and identify what evidence would be required to justify further investment.

The strongest candidates are those with a clear scientific rationale and a credible route to testing it. Novelty alone is not enough.

Three priorities can help executives direct resources more effectively:

• Preserve institutional knowledge. Retain trial results, negative findings, compound characteristics, and development decisions in accessible, well-structured records. A discontinued programme should not become an evidence gap simply because the original team has moved on.
• Prioritise candidates systematically. Compare biological rationale, safety, unmet medical need, feasibility, and commercial incentives. Apply consistent criteria rather than allowing an exciting new hypothesis to dominate the decision.
• Build partnerships early. Collaborations between pharmaceutical companies, academic researchers, public institutions, and specialist developers can help bridge funding, data-access, and expertise gaps.

Computational screening and artificial intelligence may help identify overlooked relationships between compounds and diseases. Their value depends on the quality of the underlying evidence and the ability to test predictions experimentally.

A plausible connection is the beginning of a research programme, not its final result.

Image

Drug resurrection also needs disciplined stopping rules. Teams should define what would count as convincing evidence before launching a new study. If the mechanism proves weak, the safety profile remains unacceptable, or the proposed benefit cannot justify the investment, the programme should stop.

Halloween offers an entertaining metaphor for these returning molecules, but the commercial lesson is serious.

A compound should not be revived simply because it can be. It should be revived because new evidence gives the team a defensible reason to believe that another drug development path could work.

At Pharmatica, we examine the science, investment decisions, and development strategies that shape early-stage Drug Discovery. The aim is to help industry leaders distinguish genuine opportunities from attractive but unsupported hypotheses.

Pharmatica: Insight. Connection. Impact.